本报（chinatimes.net.cn）记者郭怡琳 于娜 北京报道 在人工心脏领域，一封关切函激起关于科学透明、术语严谨与患者安危的层层波澜。 近日，国际人工器官联合会官方期刊《Artificial Organs（人工器官）》刊登了标题为"Expression of Concern（关切函）"的致编辑信，矛头直指当前人工心脏血泵技术术语使用混乱。一枚仅90克重的人工 心脏，能否被冠以"全磁悬浮"之名，成为全球顶尖科学家和企业交锋的焦点。 据悉，该文作者为美国人工器官学会终身成就奖获得者Kurt Dasse博士。其严厉指出，"CorHeart 6的核 心技术被独立专家描述为'配备了磁力辅助的双流体动力轴承的离心泵'。"而该产品制造商宣称为"全磁 悬浮装置"。 Kurt Dasse接受《华夏时报》记者采访时表示，"我撰写此文旨在提高业界意识。随着新的机械辅助装置 进入市场，有必要对装置血液相容性产生重大影响的基础技术描述、分类和透明度进行标准化。轴承技 术的差异直接影响血液损伤机制，甚至关系到患者安全。更具体地说，需要规范描述血泵中用于主要运 行模式的轴承类别。" 术语迷雾 心力衰竭是一种心血管病发展到终末期的 ...

Core Insights - CorWave has successfully completed the world's first human implantation of its innovative LVAD based on unique wave membrane technology in Australia, marking a significant milestone in sustainable mechanical circulatory support technology [1][2][4] - The CorWave LVAD is designed to significantly reduce common severe complications associated with existing LVADs, such as stroke, bleeding, heart failure, and valve disease, while improving patient quality of life and promoting heart function recovery [4][9] - The device operates at an average blood flow rate of 5-6 L/min, providing comprehensive support for patients with advanced heart failure, and is capable of dynamically adjusting blood flow based on the patient's condition [9][12] Clinical Research - CorWave LVAD has demonstrated excellent preclinical results, having safely operated in animal models for six months without any device-related complications or thrombosis, indicating its potential for clinical application [18] - The device's unique control algorithms allow for synchronized support with the patient's heartbeat, enhancing its reliability and safety [18] Market Overview - The global LVAD market was valued at approximately $2.38 billion in 2023 and is projected to grow to $5.5 billion by 2035, with a compound annual growth rate (CAGR) of 7.23% [18][20] - North America held the largest market share in 2020, while the Asia-Pacific region is expected to achieve the highest CAGR of 19.3% in the coming years due to improvements in medical facilities and government support for medical technology [20] Competitor Landscape - As of now, four domestic companies have received approval for implantable LVADs in China, including Yongrenxin Medical, Tongxin Medical, Aerospace Taixin, and Core Medical [21] - Yongrenxin Medical's EVAHEART is the only approved artificial heart in China that can be used for both short-term and long-term treatment, showcasing significant clinical success [22][24] - Tongxin Medical's CH-VAD, which utilizes next-generation magnetic levitation technology, has broken Abbott's monopoly in the market and has gained international recognition for its performance [29]